Neurones
NRO
ISIN FR0004050250 / Valor 837153
Neurones
UMushroom community rating:
About company
Neurones is a prominent entity in the field of consulting and IT services, leveraging the expertise of over 6,700 professionals. The company operates through a structured approach, dividing its operations into three main business segments to cater to the diverse needs of its clientele. These segments encompass a broad spectrum of services, including management consulting, organizational consulting, and digital transformation initiatives. Additionally, Neurones offers a comprehensive range of IT services, covering both infrastructure and application development. The firm is distinguished by its employment of consultants who bring a wealth of experience from their tenure at major international firms, ensuring a high level of expertise and service delivery. This strategic positioning allows Neurones to address the complex challenges of digital and organizational transformation faced by businesses today.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (16.10.2025):
Neurones reported a net profit increase of 6.3% for the first half of 2025, demonstrating robust financial performance and sustained growth in its operations.
Second Quarter Organic Growth
Organic growth rose by 5.3% in the second quarter of 2025, highlighting the company’s ability to expand its core business activities effectively.
First Half Net Profit
The net profit for the first half of 2025 increased by 6.3%, reflecting strong revenue generation and efficient cost management.
First Quarter Performance
In the first quarter of 2025, organic growth saw a 3.9% increase, setting a positive trend for the subsequent quarters.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1192 M
Market cap (USD)
2,735
Daily traded volume (Shares)
44.3 / 43.35
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
